Stage
No active trials
Next date
None yet
Trials
0 active
2 in total
Targets
—
None known yet
What this is
- How it works
- An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
- Tested for
- Ankylosing Spondylitis, Plaque Psoriasis
- Main trialPhase 3
- “The goal of this clinical trial is to To evaluate the efficacy of subcutaneous (SC) Netakimab in adult Chinese patients with Active Ankylosing Spondylitis. Researchers will compare Netakimab to placebo to see if Netakimab works to treat Ankylosing Spondylitis.”In the company’s words, NCT07277179 on ClinicalTrials.gov
Other drugs for Ankylosing Spondylitis
- LNK01001Lynk Pharmaceuticals Co., Ltd · Phase 3
- JitongningTasly · Phase 3
- 6083SBio · Phase 3
- HS_SW01 cellsShenzhen Huishan Biotechnology Co., Ltd. · Phase 1/2
- VilamakitugXBiotech, Inc. · Phase 2
- HB0017Huahai Pharmaceutical (Huaota) · Phase 1
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Completed | 5 Jul 2024 | Evaluate the Efficacy, Safety, and Pharmacokinetic Profile and Immunogenicity of Subcutaneous Netakimab in Chinese Adult Patients With Active Ankylosing Spondylitis | |
| Phase 3Completed | 28 Mar 2025 | To Evaluate the Efficacy and Safety of Netakimab in Chinese Patients With Moderate to Severe Plaque Psoriasis |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026